FibroBiologics, Inc.
Pharmaceutical Preparations · HOUSTON
Moderate confidence (50%)
Updated Oct 14, 2026, 12:02 AM
What is happening
Derived by rule set status-rules-2026.09.7
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
Latest material event: FibroBiologics, Inc. received a delisting notice from its exchange (Jul 22, 2026)
Timeline
Every material event, newest first. History is never overwritten.
FibroBiologics, Inc. received a delisting notice from its exchange
Jul 22, 2026
Delisting notice received
- SEC EDGAR — “Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On July 22, 2026, FibroBiologics, Inc. (the Company ) received a Staff Determination letter (the Staff Determination ) from the Listing Qualifications Department of The Nasdaq Stock Market LLC ( Nasdaq ) notifying the Company that Nasdaq Staff had determined to delist the Company s securities from The Nasdaq Capital Market. The Staff Determination stated that the bid price of the Company s listed securities had closed at less than $1.00 per share over the previous 30 consecutive busin…”
FibroBiologics, Inc. received a delisting notice from its exchange
Feb 3, 2026
Delisting notice received
- SEC EDGAR — “Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on August 4, 2025, FibroBiologics, Inc. (the Company ) received a letter from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ( Nasdaq ) notifying the Company that its market value of listed securities ( MVLS ) had closed below the minimum $35 million threshold required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the MVLS Rule ) for the previous 30 consecutive trading day period. In acco…”
FibroBiologics, Inc. received a delisting notice from its exchange
Dec 30, 2025
Delisting notice received
- SEC EDGAR — “Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on July 1, 2025, FibroBiologics, Inc. (the Company ) received a letter from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ( Nasdaq ) notifying the Company that the bid price for the Company s shares of common stock had closed below the minimum threshold of $1.00 per share, as required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the Rule ), for the previous 30 consecutive trading day pe…”
Company information
- Founded
- —
- Employees (estimate)
- —
- Industry
- Pharmaceutical Preparations
- Subindustry
- —
- Listing
- SEC lists the ticker FBLG on Nasdaq.
- SEC CIK
- 0001958777
- Website
- —
- —
- Headquarters
- HOUSTON
- Also known as
- FibroBiologics Inc.
- Legal entities
- FibroBiologics, Inc.
Sources
Every material source used to build this profile.
SEC Company Submissions (TIER 1 · UNVERIFIED)
FibroBiologics, Inc. — Pharmaceutical Preparations (SIC 2834) — HOUSTON, TX
View source recordSEC EDGAR (TIER 1 · UNVERIFIED)
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on August 4, 2025, FibroBiologics, Inc. (the Company ) received a letter from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ( Nasdaq ) notifying the Company that its market value of listed securities ( MVLS ) had closed below the minimum $35 million threshold required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the MVLS Rule ) for the previous 30 consecutive trading day period. In acco…
View source recordSEC EDGAR (TIER 1 · UNVERIFIED)
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on July 1, 2025, FibroBiologics, Inc. (the Company ) received a letter from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ( Nasdaq ) notifying the Company that the bid price for the Company s shares of common stock had closed below the minimum threshold of $1.00 per share, as required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the Rule ), for the previous 30 consecutive trading day pe…
View source recordSEC EDGAR (TIER 1 · UNVERIFIED)
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On July 22, 2026, FibroBiologics, Inc. (the Company ) received a Staff Determination letter (the Staff Determination ) from the Listing Qualifications Department of The Nasdaq Stock Market LLC ( Nasdaq ) notifying the Company that Nasdaq Staff had determined to delist the Company s securities from The Nasdaq Capital Market. The Staff Determination stated that the bid price of the Company s listed securities had closed at less than $1.00 per share over the previous 30 consecutive busin…
View source record
Status history
Every derived status, with the rule that produced it.
- DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:31 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:13 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 15, 2026, 12:34 PM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 12, 2026, 12:15 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- UNKNOWN → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 8, 2026, 03:27 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.